Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV002222588 | SCV005620301 | likely pathogenic | Autosomal recessive limb-girdle muscular dystrophy | 2025-01-08 | reviewed by expert panel | curation | The NM_000232.5: c.265G>A variant in SGCB is a missense variant predicted to cause substitution of valine by methionine at amino acid 89 (p.Val89Met). This variant has been detected in at least four individuals with symptoms of limb girdle muscular dystrophy. Of those individuals, one was compound heterozygous for the variant and a pathogenic variant (c.391C>T p.(Arg131Ter), 1 pt, ClinVar SCV000748307.5 internal data communication), and three patients were homozygous for the variant (1 pt, PMID: 28889091, 30838351, 29797799) (PM3_Strong). At least one of these patients displayed progressive limb girdle muscle weakness (PP4). This variant was also shown to co-segregate with autosomal recessive LGMD in one affected family member (PMID: 28889091; PP1). The highest population minor allele frequency in gnomAD v2.1.1 is 0.00003 in the Admixed American population (1/34588 exome alleles), which is lower than the LGMD VCEP threshold (<0.00009) for PM2_Supporting, meeting this criterion (PM2_Supporting). The computational predictor REVEL gives a score of 0.932, which is above the threshold of 0.7, evidence that correlates with impact to SGCB function (PP3). In summary, this variant meets the criteria to be classified as Likely Pathogenic for autosomal recessive limb girdle muscular dystrophy based on the ACMG/AMP criteria applied, as specified by the ClinGen LGMD VCEP (LGMD VCEP specifications version 1.0.0; 01/08/2025): PM3_Strong, PP4, PM2_Supporting, PP3, PP1. |
Labcorp Genetics |
RCV000666951 | SCV001592853 | pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2E | 2024-03-11 | criteria provided, single submitter | clinical testing | This sequence change replaces valine, which is neutral and non-polar, with methionine, which is neutral and non-polar, at codon 89 of the SGCB protein (p.Val89Met). This variant is present in population databases (rs762652676, gnomAD 0.003%). This missense change has been observed in individual(s) with limb-girdle muscular dystrophy (PMID: 15938573). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 551805). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt SGCB protein function with a negative predictive value of 80%. For these reasons, this variant has been classified as Pathogenic. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV002222588 | SCV002500418 | pathogenic | Autosomal recessive limb-girdle muscular dystrophy | 2022-03-16 | criteria provided, single submitter | clinical testing | Variant summary: SGCB c.265G>A (p.Val89Met) results in a conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 8e-06 in 251442 control chromosomes (gnomAD). c.265G>A has been reported in the literature in multiple homozygous individuals affected with Limb-Girdle Muscular Dystrophy, Autosomal Recessive (e.g. Tasca_2018, Diniz_2017, Yis_2018, Feng_2018). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014, and classified the variant as pathogenic or as uncertain significance. Based on the evidence outlined above, the variant was classified as pathogenic. |
Revvity Omics, |
RCV000666951 | SCV003808149 | likely pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2E | 2023-09-20 | criteria provided, single submitter | clinical testing | |
Neuberg Centre For Genomic Medicine, |
RCV000666951 | SCV004171903 | likely pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2E | criteria provided, single submitter | clinical testing | ||
Baylor Genetics | RCV000666951 | SCV005056708 | likely pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2E | 2023-11-25 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000666951 | SCV005665319 | likely pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2E | 2024-03-07 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000666951 | SCV000791328 | uncertain significance | Autosomal recessive limb-girdle muscular dystrophy type 2E | 2017-05-10 | flagged submission | clinical testing |